Received Mar 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | Y011819 | — |
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | Y011819 | — |
Caller confirmed no side effects/symptoms reported at this time; Caller is a nurse who reports they had a patient that received a dose of CAPVAXIVE on 2/13/2025 and an additional dose on 3/14/2025.; This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 13-FEB-2025 and on 14-MAR-2024, the patient was vaccinated with the first and second dose respectively of pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE), lot #Y011819, which has been verified to be valid lot number for pneumococcal 21-valent Conjugate Vaccine, expiration date reported and upon internal validation establish as 01-OCT-2025 (strength, exact quantity volume, route and anatomical site of administration were not reported), administered for prophylaxis (Inappropriate schedule of product administration). The reported confirmed no side effects or symptoms at this time (No adverse event).